We’d love to hear your feedback on this activity. It helps us to continually improve our products.
European Journal of Arrhythmia & Electrophysiology. 2024;10(1):Online ahead of journal publication
Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation of the vein of Marshall, renal denervation and pulmonary vein isolation have demonstrated promising results […]
Heart International. 2024;18(1):1-2
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment strategies and cutting-edge technologies to critical reviews and original research findings, each contributing to our […]
Heart International. 2024;18(1):30-37
Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 Cardiac amyloidosis is the exemplar infiltrative cardiomyopathy and is characterized by the deposition of misfolded precursor proteins into […]
Heart International. 2024;18(1):51-55
Summary Few clinical studies have shown an association between coronary artery disease (CAD) and osteoporosis. This cross-sectional study has shown that, among Indian postmenopausal women, the prevalence of CAD increases across lower bone mineral density categories. Femoral neck osteoporosis confers the higher odds of an underlying CAD. Osteoporosis and coronary artery disease (CAD) represent two […]
Heart International. 2024;18(1):3-4
Glucagon-like peptide 1 (GLP-1) receptor agonists piqued our interest when Marso et al. demonstrated that liraglutide significantly reduced cardiovascular events (CVEs) in persons with type 2 diabetes mellitus (T2DM) who were at a high cardiovascular (CV) risk compared with placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; ClinicalTrials.gov […]
Heart International. 2024;18(1):5-8
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1 Recent estimates suggest that over 40% of these patients continue to have uncontrolled blood pressure (BP) and that […]
Heart International. 2024;18(1):26-29
Over the past two decades, the field of transcatheter aortic valve replacement (TAVR) has experienced remarkable advancement. Initially approved for patients with high and prohibitive surgical risk, TAVR has progressively extended its indications to all patients, regardless of surgical risk. Beyond the expansion of indications, substantial efforts have been dedicated to refining and optimizing both […]
Heart International. 2024;18(1):9-25
Catheter ablation (CA) is an invasive adjunctive therapeutic option for atrial and ventricular arrhythmias, in uncontrolled cases, following optimal medical therapy.1,2 The validation of 3D mapping and its implementation into clinical usage has been a remarkable achievement in the field of complex ablation of scar-related ventricular tachycardia (VT) in the early 2000s.3 In the setting of atrial […]
Heart International. 2024;18(1):44-50
Cardiovascular disease (CVD) continues to be the leading cause of death on a global scale. Nearly 18 million people died from CVD in 2019, accounting for about one-third of all deaths globally.1 The primary cause of CVD-related death and morbidity is ischaemic heart disease (IHD). Since 1990, the total number of disability adjusted life years (DALYs) […]
Get the latest clinical insights from touchCARDIO